Project Grant HT94252410991
Award Date
8/15/24
Completion Date
8/14/28
Dollars Obligated
$7M
Federal Agency
Defense Health Agency
Federal Grant Program
12.420
Assistance Type
Project Grant
Place of Performance
Houston, TX 77030, USA
Similar Awards
This $1,619,723 federal Project Grant award from the Department of Defense's Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) provides funding to The University of Texas MD Anderson Cancer Center to conduct research targeting novel mediators of breast cancer brain metastasis. The award period runs from April 1, 2024 to March 31, 2027, with the goal of developing new treatments, improving patient care, and advancing scientific understanding in this...
The Defense Health Agency awarded a $728,043 project grant under the Military Medical Research and Development (CFDA 12.420) program to The University of Texas MD Anderson Cancer Center. The grant, awarded on February 1, 2025, will fund research to delineate the tumor ecology and genomic progression of lobular breast cancers over a project period ending on January 31, 2028. The research aims to advance the understanding of this specific type of breast cancer and explore innovative approaches...
This $3,945,543 Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) supports cancer research and care initiatives at the University of Texas MD Anderson Cancer Center (MD Anderson). The award will fund a 4-year clinical research extension project to advance progress, precision, and equity in breast cancer care. MD Anderson, a leading comprehensive cancer center, will utilize the funding to conduct research activities that...
The Department of Defense's Military Medical Research and Development program (CFDA 12.420) awarded a $1,619,668 project grant to The University of Texas MD Anderson Cancer Center to inhibit brain metastases of HER2/neu-positive breast cancers using extracellular vesicles from renovated dendritic cells. The award began on May 1, 2024 and is scheduled for completion on April 30, 2027. The project aims to develop innovative treatments to improve outcomes for military service members and the...
The University of Texas MD Anderson Cancer Center received a $567,000 Project Grant from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420). The grant, awarded on September 1, 2024, will fund research targeting myeloid mimicry in renal medullary carcinoma, with a completion date of August 31, 2027. Through this federal grant, MD Anderson Cancer Center will conduct innovative scientific studies, ranging from basic laboratory research to advanced...
This federal Project Grant award, valued at $1,635,000.00 and funded by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program, supports research at the University of Texas MD Anderson Cancer Center to target a driver kinase, PCTK1, in combination with a ferroptosis inducer to combat breast cancer brain metastasis. The research aims to transform healthcare for military service members and the broader public by investigating innovative approaches to...
The federal Project Grant award of $735,799.00 was provided by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program. The grant is awarded to the University of Texas MD Anderson Cancer Center to support the project "INNOVATING BREAST CANCER RNA THERAPY: MECHANISMS AND PHARMACOGENETIC INHIBITORS". The project aims to conduct advanced biomedical research focused on transforming healthcare for military service members and the broader public,...
The Defense Health Agency awarded a $1.5 million Project Grant to The University of Texas M.D. Anderson Cancer Center through January 31, 2026 to investigate the role of MELK in stromal reorganization of aggressive breast cancers. The grant is funded through the Military Medical Research and Development program (CFDA 12.420), which supports biomedical research to improve health care for service members and the public. Specifically, the grant will fund research to transform cancer treatment by...
The University of Texas MD Anderson Cancer Center received a $647,990 Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420). This three-year grant, effective June 1, 2024, supports research to investigate cell plasticity and epigenetic reprogramming mechanisms underlying the transition of well-differentiated to de-differentiated liposarcoma. The funding will enable basic research, translational studies, and potentially future...
This federal Project Grant award, valued at $505,071.00, was provided by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program. The grant supports research conducted by the University of Texas MD Anderson Cancer Center to discover noncanonical antigens in triple-negative breast cancer for the development of novel T cell therapies. The project will run from February 15, 2025 to February 14, 2028, focusing on advanced cancer research and exploring...